TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17973730

Group type: EXPERIMENTAL
Intervention: Health Promotion Health Center (HPHC) programs
Number of subjects: 2261

Group type: COMPARATOR
Intervention: Non-HPHC sites (Control)
Number of subjects: 2261
Study: 15310739

Group type: EXPERIMENTAL
Intervention: 400 microg Cr picolinate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 800 microg Cr picolinate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 11555446

Group type: EXPERIMENTAL
Intervention: Cervical length assessment
Number of subjects: 6334

Group type: EXPERIMENTAL
Intervention: Funneling of the internal os
Number of subjects: 6334

Group type: COMPARATOR
Intervention: Cervical length and funneling
Number of subjects: 6334
Study: 9750527

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy for 2 years
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control (immediate surgery)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy for 2 years (stage C cancer)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control (immediate surgery, stage C cancer)
Number of subjects: 176
Study: 7825970

Group type: EXPERIMENTAL
Intervention: Monitoring of 5FU based on pharmacokinetic information
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard dose of 5FU
Number of subjects: 38
Study: 3339175

Group type: EXPERIMENTAL
Intervention: Catheter (11F diameter, tripolar, distal platinum‐iridium tip for pacing, middle 4.3 cm2 platinum electrode at right ventricular apex, proximal 8.5 cm2 platinum electrode at superior vena cava-right atrial junction)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Superior vena cava spring-left ventricular patch electrode system (6.7 cm2 anode, 13.5 cm2 cathode)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Catheter
Number of subjects: 15

Group type: COMPARATOR
Intervention: Spring-patch system
Number of subjects: 15
Study: 29550013

Group type: EXPERIMENTAL
Intervention: Reciproc Blue (REC Blue; VDW, Munich, Germany)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HyFlex EDM (HEDM; Coltene/Whaledent, Altstätten, Switzerland)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: XP‐endo Shaper (XPS; FKG Dentaire SA, La Chaux‐de‐Fonds, Switzerland)
Number of subjects: 60
Study: 27716446

Group type: EXPERIMENTAL
Intervention: MFES-assisted gait training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional gait training
Number of subjects: 40
Study: 24872563

Group type: EXPERIMENTAL
Intervention: EEG-based channel tuning functions (CTFs) during the orientation WM task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postsample cue to store or drop the memorandum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instruction to store one of two simultaneously presented stimuli
Number of subjects: 0
Study: 23025129

Group type: EXPERIMENTAL
Intervention: Healing Touch with Guided Imagery (HT+GI)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 123
Study: 20203627

Group type: EXPERIMENTAL
Intervention: 6 g/day of flavanol-rich dark chocolate
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 25 g/day of flavanol-rich dark chocolate
Number of subjects: 102
Study: 18752690

Group type: EXPERIMENTAL
Intervention: quetiapine/CBT
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo/CBT
Number of subjects: 31
Study: 16521846

Group type: EXPERIMENTAL
Intervention: 8% CHO + 2% protein (CHO-P)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 6% CHO (CHO6)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 10% CHO (CHO10)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 km time trial
Number of subjects: 8
Study: 12004845

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 3118

Group type: COMPARATOR
Intervention: Control (no adjuvant chemotherapy)
Number of subjects: 3118
Study: 10326149

Group type: EXPERIMENTAL
Intervention: New thrombolytic agents (including reteplase, TNK-t-PA, lanoteplase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolytics combined with new glycoprotein IIb/IIIa platelet inhibitors and anti-thrombin agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current thrombolytics
Number of subjects: 0
Study: 8941528

Group type: EXPERIMENTAL
Intervention: Bench-press training with heavy loads
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bench-press training with light loads
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alternative training group using different exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group that did not train
Number of subjects: 40
Study: 1828659

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg/day (treatment A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ramipril 1.25 mg/day (treatment B)
Number of subjects: 16
Study: 6940466

Group type: EXPERIMENTAL
Intervention: High-dose induction chemotherapy (TAD) consisting of 6-thioguanine, cytarabine, and daunorubicin
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intensive consolidation chemotherapy followed by maintenance chemotherapy with immunotherapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intensive consolidation chemotherapy followed by maintenance chemotherapy without immunotherapy
Number of subjects: 68
Study: 31862620

Group type: EXPERIMENTAL
Intervention: High screen time (HST, ST > 6 h/day)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Light- and moderate-intensity physical activity (LMPA)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Both low screen time (LST) and light- and moderate-intensity physical activity (LMPA)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Both high screen time (HST) and vigorous-intensity physical activity (VIPA)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Both high screen time (HST) and light- and moderate-intensity physical activity (LMPA)
Number of subjects: 1137
Study: 31775859

Group type: EXPERIMENTAL
Intervention: Intravaginal lactic acid gel 5 ml once daily for 7 days
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Oral metronidazole tablets 400 mg twice daily for 7 days
Number of subjects: 1900
Study: 28287054

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention for 45 minutes once a week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention for 15 minutes three times a week (total 45 minutes per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only (control group)
Number of subjects: 0
Study: 26350343

Group type: EXPERIMENTAL
Intervention: Clinical assessment with non-invasive tests plus invasive urodynamic testing (IUT)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Clinical assessment with non-invasive tests (control arm)
Number of subjects: 222
Study: 23246229

Group type: EXPERIMENTAL
Intervention: Berberine gelatin (5 mg/g) applied 4 times per day for 5 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo gelatin
Number of subjects: 84
Study: 21413865

Group type: EXPERIMENTAL
Intervention: Micronutrient supplement containing 12 vitamins and 9 minerals
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 19684155

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment for 12 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etanercept treatment for nonresponders after 12 months of MTX
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 15980646

Group type: EXPERIMENTAL
Intervention: Vaginal termination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral misoprostol termination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-amniotic injection of prostaglandin termination
Number of subjects: 0
Study: 12909504

Group type: EXPERIMENTAL
Intervention: recombinant FSH‐alpha (150 IU/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: hMG (150 IU/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study: 10560790

Group type: EXPERIMENTAL
Intervention: Single microbead diltiazem delivery system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dual microbead diltiazem delivery system
Number of subjects: 40
Study: 8712394

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo oralet
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: OTFC
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: OTFC, Placebo, Control
Number of subjects: 90
Study: 2015974

Group type: EXPERIMENTAL
Intervention: Serum 1,5-anhydroglucitol (AG) levels
Number of subjects: 1620

Group type: COMPARATOR
Intervention: HbA1c
Number of subjects: 1620

Group type: COMPARATOR
Intervention: Fructosamine (FA)
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: AG and HbA1c together
Number of subjects: 1620
Study: 6633618

Group type: EXPERIMENTAL
Intervention: Single-dose therapy with trimethoprim/sulfamethoxazole (43 courses)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Single-dose therapy with tobramycin (23 courses)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Therapy to eradicate bacteriuria
Number of subjects: 88

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mortality and infectious morbidity after randomization
Number of subjects: 88
Study: 29952801

Group type: EXPERIMENTAL
Intervention: Extreme pump position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HeartMate II pump position at implant
Number of subjects: 0
Study: 28145818

Group type: EXPERIMENTAL
Intervention: Health education, diet supervision and exercise supervision (twice a week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normal lifestyle)
Number of subjects: 60
Study: 26054185

Group type: EXPERIMENTAL
Intervention: Dentifrices containing 1.5% arginine, 1450 ppm fluoride as sodium monofluorophosphate (MFP), and an insoluble calcium compound (either dicalcium phosphate or calcium carbonate)
Number of subjects: 5500

Group type: COMPARATOR
Intervention: Positive control dentifrice containing 1450 ppm fluoride as sodium fluoride (NaF)
Number of subjects: 5500
Study: 23686738

Group type: EXPERIMENTAL
Intervention: Monthly ibandronate (150 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Weekly alendronate (70 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 42
Study: 21158903

Group type: EXPERIMENTAL
Intervention: Multimedia education programme (n=46)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional stoma education programme (n=56)
Number of subjects: 102
Study: 19572297

Group type: EXPERIMENTAL
Intervention: Titanium membrane
Number of subjects: 32

Group type: COMPARATOR
Intervention: e-PTFE membrane
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (Titanium and e-PTFE)
Number of subjects: 32
Study: 17803060

Group type: EXPERIMENTAL
Intervention: Test drug (10 mg amlodipine tablet - Intervask)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference drug
Number of subjects: 12

Group type: COMPARATOR
Intervention: Test drug vs Reference drug
Number of subjects: 12
Study: 15780454

Group type: EXPERIMENTAL
Intervention: Semantic and syntactic processing evaluated on grammaticality judgement task
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Semantic and syntactic processing evaluated on sentence‐picture matching task
Number of subjects: 1
Study: 12425551

Group type: EXPERIMENTAL
Intervention: Exercise (5 min on a treadmill at a 20% incline at 10 km/h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Resting (control)
Number of subjects: 12
Study: 10483844

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT) with instructions to drop safety behaviours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard cognitive-behaviour therapy (CBT)
Number of subjects: 30
Study: 8630576

Group type: EXPERIMENTAL
Intervention: FK‐888 (2.5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1925965

Group type: EXPERIMENTAL
Intervention: Gentamicin and clindamycin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 56
Study: 7049959

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (75 mg/kg body weight)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 120
Study: 30707660

Group type: EXPERIMENTAL
Intervention: GEMOX (gemcitabine 1,000 mg/m2 on day 1 and oxaliplatin 85 mg/m2 on day 2 of a 2-week cycle for 12 cycles)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Surveillance (standard arm B)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: GEMOX
Number of subjects: 196

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 196
Study: 29530071

Group type: EXPERIMENTAL
Intervention: Intervention phase (multidisciplinary team intervention)
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Intervention phase
Number of subjects: 1071
Study: 27265507

Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg
Number of subjects: 1326

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1326
Study: 24493666

Group type: EXPERIMENTAL
Intervention: Isokinetic rehabilitation programme
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Hamstring concentric strength at 60°/s
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Hamstring concentric strength at 300°/s
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Hamstring eccentric strength
Number of subjects: 52

Group type: COMPARATOR
Intervention: Players without reinjury (N=46)
Number of subjects: 52
Study: 23031143

Group type: EXPERIMENTAL
Intervention: Telemonitoring adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phone visits adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictors of adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between telemonitoring and phone visits
Number of subjects: 0
Study: 20576804

Group type: EXPERIMENTAL
Intervention: Blood pressure control goal of <130/80 mmHg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational data and secondary analyses
Number of subjects: 0
Study: 17953922

Group type: EXPERIMENTAL
Intervention: 0.9% isotonic saline
Number of subjects: 71

Group type: COMPARATOR
Intervention: 0.45% hypotonic saline
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both isotonic and hypotonic saline
Number of subjects: 71
Study: 16391723

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12413183

Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interview (ACASI)
Number of subjects: 1142

Group type: COMPARATOR
Intervention: Interviewer-administered questionnaires (IAQ)
Number of subjects: 1142
Study: 9857596

Group type: EXPERIMENTAL
Intervention: 35% phosphoric etching gel (pH 1) applied in the peri-implant sulcus
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control therapy with supra- and subgingival debridement using carbon fiber curettes and a rubber cup
Number of subjects: 16
Study: 8730504

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combined low antigen diet and therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Unrestrained diet
Number of subjects: 63
Study: 2215608

Group type: EXPERIMENTAL
Intervention: ursodiol
Number of subjects: 600

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: all patients
Number of subjects: 600
Study: 101263

Group type: EXPERIMENTAL
Intervention: Early return to work (advised to return to work early)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Standard return to work (supervised by general practitioner)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Early return to work
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Loss of earnings while off work
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Economic benefit of early return to work
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Recurrence rate at 1 year
Number of subjects: 295
Study: 29617953

Group type: EXPERIMENTAL
Intervention: High stressors
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: High resources
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: School stressors and resources
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Friend stressors and resources
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Family resources
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Severe TBI
Number of subjects: 152
Study: 26575180

Group type: EXPERIMENTAL
Intervention: Bupivacaine lozenge
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 18
Study: 25102882

Group type: EXPERIMENTAL
Intervention: SLM deposition basal crowns
Number of subjects: 168

Group type: COMPARATOR
Intervention: Cobalt chromium alloy casting base crowns
Number of subjects: 168
Study: 23131885

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (up to 2400 mg/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 20691553

Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy (RT) before direct stenting (DS)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Direct stenting (DS) alone
Number of subjects: 501
Study: 18517289

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 15960563

Group type: EXPERIMENTAL
Intervention: Sertraline (50-100 mg/day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 12949359

Group type: EXPERIMENTAL
Intervention: High sterol margarine (1.5 g/d plant sterols + 0.5 g/d plant stanols)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low sterol margarine (1 g/d plant sterols + 1 g/d plant stanols)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High sterol margarine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low sterol margarine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both mixtures (high and low sterol margarines)
Number of subjects: 44
Study: 10536548

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional laryngeal mask
Number of subjects: 25
Study: 9735593

Group type: EXPERIMENTAL
Intervention: Negative affectivity (NA)
Number of subjects: 97
Study: 1867552

Group type: EXPERIMENTAL
Intervention: Timolol instillation in one eye
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fellow, untreated eye
Number of subjects: 10
Study: 6417606

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 50
Study: 30819227

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 96

Group type: COMPARATOR
Intervention: Venturi mask oxygen therapy
Number of subjects: 96
Study: 29727403

Group type: EXPERIMENTAL
Intervention: Breaking sitting (walking for 2 min every 20 min over 5.5 h)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Prolonged sitting
Number of subjects: 11
Study: 27511325

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 24633056

Group type: EXPERIMENTAL
Intervention: UrgoClean dressing
Number of subjects: 159

Group type: COMPARATOR
Intervention: Aquacel dressing
Number of subjects: 159
Study: 22350834

Group type: EXPERIMENTAL
Intervention: CAPIO suturing device
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional suture ligation
Number of subjects: 50
Study: 20139767

Group type: EXPERIMENTAL
Intervention: Communicating APOE genotype and lifetime Alzheimer disease risk information
Number of subjects: 246
Study: 18695911

Group type: EXPERIMENTAL
Intervention: p-STAT3 expression in invasive CRA
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: p-STAT3 expression in invasive CRA determined by real-time PCR
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: IHC analysis of p-STAT3 expression
Number of subjects: 167

Group type: COMPARATOR
Intervention: IHC analysis of p-STAT3 expression in CRA vs adenoma and normal mucosae
Number of subjects: 167
Study: 15944779

Group type: EXPERIMENTAL
Intervention: 5-FU continuous infusion (320 mg/m2/day) for 14 days followed by oral HCFU (300 mg/day) for one year
Number of subjects: 429

Group type: COMPARATOR
Intervention: 5-FU continuous infusion alone for 14 days
Number of subjects: 429
Study: 12578919

Group type: EXPERIMENTAL
Intervention: Hippocampal atrophy (HA)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Hyperintense T2 signal
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Refractory FMTLE
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Duration of epilepsy
Number of subjects: 142
Study: 10646729

Group type: EXPERIMENTAL
Intervention: Specific local nasal immunotherapy (LNIT) for 8 months
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Specific local nasal immunotherapy (LNIT) for allergy to mites
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Specific local nasal immunotherapy (LNIT)
Number of subjects: 102
Study: 9312650

Group type: EXPERIMENTAL
Intervention: Working under harmful conditions during pregnancy (exposure to physical and/or chemical factors)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Continued work under harmful conditions by the end of the second trimester
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Exposure to chemical factors
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Exposure to physical factors
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Mother's single status, smoking during pregnancy, poor health condition during pregnancy
Number of subjects: 526
Study: 8354771

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0